Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer

Paolo Bossi, Gabriela Kornek, Gaetano Lanzetta, Antonio Rozzi, Thorsten Füreder, Laura Locati, Lisa Licitra

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: In patients with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC), there are no data about an every-other-week cetuximab maintenance schedule after chemotherapy plus cetuximab as first-line treatment. Methods: We reviewed the safety and feasibility of every-other-week maintenance cetuximab administered at 3 different European centers. Results: Thirty-one patients with recurrent or metastatic HNSCC were treated from 2006 to 2010. Mean cetuximab dose intensity in the maintenance phase was 93%. The major toxicities reported during every-other-week maintenance cetuximab were skin rash (grade 3, 16%; grade 2, 23%), fatigue (grade 3, 3%; grade 2, 16%), diarrhea (grade 3, 7%; grade 2, 13%), hypomagnesemia (grade 4, 3%; grade 3, 3%; grade 2, 19%), and mucositis (grade 3, 3%; grade 2, 23%). Conclusions: Every-other-week maintenance cetuximab schedule was well tolerated and did not worsen toxicity that occurred during chemotherapy. In daily practice, this simplified schedule could improve compliance and possibly improve quality of life in patients with recurrent or metastatic HNSCC that showed no progression during first-line chemotherapy.

Original languageEnglish
Pages (from-to)1471-1474
Number of pages4
JournalHead and Neck
Volume35
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Squamous Cell Neoplasms
Head and Neck Neoplasms
Head
Maintenance
Safety
Drug Therapy
Appointments and Schedules
Mucositis
Exanthema
Compliance
Fatigue
Cetuximab
Diarrhea
Quality of Life

Keywords

  • every-other-week cetuximab
  • maintenance therapy
  • quality of life
  • recurrent and/or metastatic head and neck cancer

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. / Bossi, Paolo; Kornek, Gabriela; Lanzetta, Gaetano; Rozzi, Antonio; Füreder, Thorsten; Locati, Laura; Licitra, Lisa.

In: Head and Neck, Vol. 35, No. 10, 10.2013, p. 1471-1474.

Research output: Contribution to journalArticle

@article{ce33eb2bb953494498d1f7427d1066cf,
title = "Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer",
abstract = "Background: In patients with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC), there are no data about an every-other-week cetuximab maintenance schedule after chemotherapy plus cetuximab as first-line treatment. Methods: We reviewed the safety and feasibility of every-other-week maintenance cetuximab administered at 3 different European centers. Results: Thirty-one patients with recurrent or metastatic HNSCC were treated from 2006 to 2010. Mean cetuximab dose intensity in the maintenance phase was 93{\%}. The major toxicities reported during every-other-week maintenance cetuximab were skin rash (grade 3, 16{\%}; grade 2, 23{\%}), fatigue (grade 3, 3{\%}; grade 2, 16{\%}), diarrhea (grade 3, 7{\%}; grade 2, 13{\%}), hypomagnesemia (grade 4, 3{\%}; grade 3, 3{\%}; grade 2, 19{\%}), and mucositis (grade 3, 3{\%}; grade 2, 23{\%}). Conclusions: Every-other-week maintenance cetuximab schedule was well tolerated and did not worsen toxicity that occurred during chemotherapy. In daily practice, this simplified schedule could improve compliance and possibly improve quality of life in patients with recurrent or metastatic HNSCC that showed no progression during first-line chemotherapy.",
keywords = "every-other-week cetuximab, maintenance therapy, quality of life, recurrent and/or metastatic head and neck cancer",
author = "Paolo Bossi and Gabriela Kornek and Gaetano Lanzetta and Antonio Rozzi and Thorsten F{\"u}reder and Laura Locati and Lisa Licitra",
year = "2013",
month = "10",
doi = "10.1002/hed.23170",
language = "English",
volume = "35",
pages = "1471--1474",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer

AU - Bossi, Paolo

AU - Kornek, Gabriela

AU - Lanzetta, Gaetano

AU - Rozzi, Antonio

AU - Füreder, Thorsten

AU - Locati, Laura

AU - Licitra, Lisa

PY - 2013/10

Y1 - 2013/10

N2 - Background: In patients with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC), there are no data about an every-other-week cetuximab maintenance schedule after chemotherapy plus cetuximab as first-line treatment. Methods: We reviewed the safety and feasibility of every-other-week maintenance cetuximab administered at 3 different European centers. Results: Thirty-one patients with recurrent or metastatic HNSCC were treated from 2006 to 2010. Mean cetuximab dose intensity in the maintenance phase was 93%. The major toxicities reported during every-other-week maintenance cetuximab were skin rash (grade 3, 16%; grade 2, 23%), fatigue (grade 3, 3%; grade 2, 16%), diarrhea (grade 3, 7%; grade 2, 13%), hypomagnesemia (grade 4, 3%; grade 3, 3%; grade 2, 19%), and mucositis (grade 3, 3%; grade 2, 23%). Conclusions: Every-other-week maintenance cetuximab schedule was well tolerated and did not worsen toxicity that occurred during chemotherapy. In daily practice, this simplified schedule could improve compliance and possibly improve quality of life in patients with recurrent or metastatic HNSCC that showed no progression during first-line chemotherapy.

AB - Background: In patients with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC), there are no data about an every-other-week cetuximab maintenance schedule after chemotherapy plus cetuximab as first-line treatment. Methods: We reviewed the safety and feasibility of every-other-week maintenance cetuximab administered at 3 different European centers. Results: Thirty-one patients with recurrent or metastatic HNSCC were treated from 2006 to 2010. Mean cetuximab dose intensity in the maintenance phase was 93%. The major toxicities reported during every-other-week maintenance cetuximab were skin rash (grade 3, 16%; grade 2, 23%), fatigue (grade 3, 3%; grade 2, 16%), diarrhea (grade 3, 7%; grade 2, 13%), hypomagnesemia (grade 4, 3%; grade 3, 3%; grade 2, 19%), and mucositis (grade 3, 3%; grade 2, 23%). Conclusions: Every-other-week maintenance cetuximab schedule was well tolerated and did not worsen toxicity that occurred during chemotherapy. In daily practice, this simplified schedule could improve compliance and possibly improve quality of life in patients with recurrent or metastatic HNSCC that showed no progression during first-line chemotherapy.

KW - every-other-week cetuximab

KW - maintenance therapy

KW - quality of life

KW - recurrent and/or metastatic head and neck cancer

UR - http://www.scopus.com/inward/record.url?scp=84884904170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884904170&partnerID=8YFLogxK

U2 - 10.1002/hed.23170

DO - 10.1002/hed.23170

M3 - Article

VL - 35

SP - 1471

EP - 1474

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 10

ER -